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Abstract: Background: Small bowel adenocarcinoma (SBA) is a rare yet insidious cancer with poor
survival. The abundance of tumour-infiltrating lymphocytes is associated with improved survival,
but the role of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway in
tumour escape is controversial. We evaluated immune cell infiltration, PD1/PD-L1 expression and
their prognostic value in a series of SBAs with previously verified predisposing conditions and
exome-wide somatic mutation characterization. Methods: Formalin-fixed paraffin-embedded tissue
sections stained for CD3, CD8, PD-L1 and PD-1 were analysed from 94 SBAs. An immune cell score
(ICS) was formed from the amount of the CD3 and CD8 positive lymphocytes from the tumour centre
and invasive margin. The PD-L1 and PD-1 positive immune cells (ICs) and ICS were combined into a
variable called Immunoprofile. Results: High ICS, PD-L1IC and PD-1, individually and combined as
Immunoprofile, were prognostic for better patient outcome. Sixty-five (69%) SBAs expressed ≥1%
positive PD-L1IC. A high tumour mutation burden was common (19%) and associated with immune
markers. Immunoprofile, adjusted for TNM stage, mismatch repair status, tumour location, sex and
age were independent prognostic markers for disease-specific and overall survival. Conclusions:
Analysing tumoral immune contexture provides prognostic information in SBA. Combining ICS,
PD-1 and PD-L1IC as Immunoprofile enhanced the prognostic performance.
Keywords: small bowel; adenocarcinoma; tumour infiltrating lymphocytes; PD-1; PD-L1
1. Introduction
The small bowel is perhaps the most powerful organ in the human body in terms of regulating the
immune system. This may explain why small bowel cancers are rare, comprising only approximately 3%
of all GI-tract malignancies [1], although the incidence rate has been increasing [2]. Adenocarcinomas
account for approximately 40% of all malignant small bowel tumours and are most commonly found
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in the duodenum (50–55%). Otherwise, 16–30% of tumours are found in the jejunum and 13–20% in
the ileum [3,4]. Usually small bowel adenocarcinoma (SBA) occurs sporadically, but it is also often
associated with several genetic predispositions, such as familial adenomatous polyposis (FAP), Lynch
syndrome (LS), Peutz–Jeghers syndrome, and juvenile polyposis. Known risk factors for SBA also
include Crohn’s disease and coeliac disease, which both cause chronic inflammation of the small
bowel [5]. Environmental factors, like smoking, alcohol, red meat, sugar and starchy foods, have been
reported to increase the risk of SBA [6]. In Crohn’s disease, the proposed additional risk factors for SBA
include proximal disease of the intestine, male gender, diagnosis at a young age, surgically created
non-functional bowel loops and the use of anti-inflammatory medications such as corticosteroids and
tumour necrosis factor alpha antibodies [7].
Small bowel adenocarcinoma is often relatively asymptomatic for a long time, with the estimated
period from first symptoms to diagnosis being 2–8 months. Therefore, SBA is discovered usually at an
advanced stage and with a poor prognosis. In early stage disease, the reported 5-year overall survival
ranges from 35% to 80%, in locally advanced disease with regional lymph node metastases 8% to 47%
and with the disseminated disease with distant metastases only 5% [8]. Crohn’s disease associated
SBA is usually located diffusely in the ileum or distal jejunum with similar symptoms as in active
or obstructive Crohn’s disease, and it is rarely suspected preoperatively, resulting in an even worse
outcome [9].
Most SBAs are believed to share a similar tumorigenesis with colorectal cancer (CRC),
i.e., pathogenesis with a similar transition from adenoma to carcinoma [8]. However, chronic
inflammation, as seen for example in Crohn’s disease, may cause SBA to arise through the
inflammation–dysplasia–adenocarcinoma sequence [8,10,11]. The reason for the large difference
between the incidence of CRC and SBA is not clear, but several possible explanations have been
proposed. The small bowel epithelium has a faster renewal rate which prevents the accumulation of
genetic damage, and the epithelial cells produce microsomal protective enzymes against food-derived
carcinogens. The transit time of small bowel contents is faster, the large volume of secretions dilutes the
concentration of carcinogens, and the low density of bacterial microbiota produce fewer carcinogenic
metabolites, limiting strain on the small bowel mucosa. Gut-associated lymphoid tissue and various
immune response-mediating cells, for example, cytotoxic CD8+ T-lymphocytes, are more prevalent in
the small intestine, suggesting greater immune surveillance [12,13].
Analysis of the tumour microenvironment has offered a novel way to predict cancer behaviour.
Antitumour immune surveillance is mainly overseen by CD8+ T-lymphocytes primed by specific
dendritic cells located in the tertiary lymphoid structures. High intratumoral infiltration of CD3+
and CD8+ cytotoxic T-lymphocytes and adjacent tertiary lymphoid structures are associated with a
favourable prognosis in patients with many different malignant tumours like melanoma, colorectal,
non-small-cell lung, breast, head and neck, pancreatic and gastric cancers [14,15]. The Immunoscore,
derived from the densities of CD3+ and CD8+ lymphocytes in the invasive margin and tumour centre,
has proven to be a strong prognostic marker, especially in CRC, and could be used alongside traditional
TNM-staging to better evaluate patient outcome [16].
Tumours with microsatellite instability (MSI) usually have a better prognosis than microsatellite
stable (MSS) tumours, probably relating to the enhanced immune reaction against the massive mutation
burden of the MSI tumours [17]. Although immune response is generally high in MSI tumours,
Immunoscore has been shown to have prognostic meaning regardless of the tumour mismatch repair
(MMR) status in colon cancer [18,19]. In SBA, the proportion of MSI tumours has been reported to vary
between 5% and 35% [20], and, overall, the fraction of SBA with a high tumour mutational burden
(TMB) seems to be greater than in CRC or gastric cancer [21].
One of the emerging hallmarks of cancer is avoiding host immune reaction by making the immune
system unable to destroy cancer cells [22]. Evading immune surveillance can be done by inhibiting
T-cell effector functions by upregulating the programmed cell death-1/programmed death ligand-1
(PD-1/PD-L1) pathway, which is seen in many cancers [22,23]. Normally, PD-1 is the surface receptor
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of an activated T-cell, and it mediates immunosuppression [24]. However, the exact role of the
PD1/PD-L1 pathway in cancer progression is still insufficiently understood, and there is evidence of
other tumour escape mechanisms, such as the local overproduction of prostaglandins that promote
immunosuppressive and regulatory immune cells, allowing immune evasion [25,26]. In our earlier
study on CRC, a high density of PD1- and PD-L1-positive immune cells were frequent in MSI tumours
and associated with a strong immune reaction and favourable prognosis [25].
Small bowel adenocarcinoma is a rare and insufficiently understood cancer with a complex
immune environment in the small bowel and several genetic or inflammatory predisposing diseases.
Based on previous work, we aimed to evaluate immune contexture, including immune cell infiltration
(Immune cell score, ICS) and PD1/PD-L1 expression, and their prognostic value in a nation-wide
series of SBA with verified predisposing conditions and previous exome-wide somatic mutation
characterization [27].
2. Results
2.1. Immune Contexture and Association with Other Clinicopathological Parameters
Immune cell score was ICS0 in 27 (29%), ICS1 in 14 (15%), ICS2 in 17 (18%), ICS3 in 11 (12%) and
ICS4 in 24 (26%) tumours. A high number of PD-1 positive lymphocytes were expressed in 27 tumours
(29%) including all the LS tumours. The PD-L1 positive immune cells (PD-L1IC) were expressed at
>5% with moderate-to-strong staining intensity in 24 (26%) and PD-L1 positive tumour cells (PD-L1TC)
in seven (7%) tumours. Although the >5% threshold was, here, selected for survival analysis, PD-L1IC
and PD-L1TC with a ≥1% expression and moderate-to-strong staining intensity were observed in 65
(69%) and 14 (15%) tumours, respectively. Including tumours with weak staining intensity, a ≥1%
expression of PD-L1IC in 85% and PD-L1TC was seen in 21% of the tumours. Immunoprofile was class
0 in 41 (44%), class 1 in 21 (22%), class 2 in 11 (12%) and class 3 in 19 (20%) tumours.
Immune cell score in association with other clinicopathological variables is shown in Table 1.
Low ICS (0–2) and high ICS (3–4) did not associate statistically significantly with age, sex, tumour
location, or coeliac disease. However, high ICS was associated with MSI (p = 0.005) and lower TNM
stage (p = 0.022). Three of the four LS tumours had ICS4 and three of the four Crohn’s disease-associated
tumours had IS0.
High PD-1 was associated with lower TNM stage so that only 9% of the stage IV tumours and
42% of the stage I–II tumours had high PD-1 (p = 0.005). In addition, 86% of the MSI tumours had high
PD-1 (p < 0.001). Positive PD-L1IC associated with MSI status (64% of the MSI tumours had positive
PD-L1IC, p < 0.001). Immune cell score, PD-1 and PD-L1IC were all strongly associated with each other
(p < 0.001). Positive PD-L1TC was only suggestively related to a higher tumour grade with 4/6 (67%
with one case missing data) having tumour grade 3 (p = 0.034). High Immunoprofile was associated
with lower TNM stage so that most of the stage IV tumours (88%) had a low Immunoprofile of 0 or
1 (p = 0.003). Immunoprofile was strongly associated with MSI status with 86% of the MSI tumours
having Immunoprofile 2 or 3 (p < 0.001). All the LS tumours had a high Immunoprofile of 2 or 3 (p =
0.018, Table 2).
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Table 1. Clinicopathological variables and their associations with Immune cell score.
Low ICS High ICS Total
p-Valuen = 58 n = 35 n = 93
(% of Row) (% of Row) (% of the Column)
Age
<60 years 23 (61) 15 (40) 38 (41)
0.761≥60 years 35 (64) 20 (36) 55 (59)
Sex
Female 29 (66) 15 (34) 44 (47)
0.504Male 29 (59) 20 (41) 49 (53)
TNM stage
I 1 (25) 3 (75) 4 (4)
0.022 *
II 11 (55) 9 (45) 20 (22)
III 12 (50) 12 (50) 24 (26)
IV 26 (76) 8 (24) 34 (37)
Tumour grade
1 10 (59) 7 (41) 17 (19)
0.889 *2 35 (63) 21 (38) 56 (63)
3 9 (56) 7 (44) 16 (18)
MMR status
MSI 4 (29) 10 (71) 14 (15)
0.005MSS 54 (68) 25 (32) 79 (85)
Tumour location
Duodenum 9 (53) 8 (47) 17 (18)
0.292Jejunum 33 (66) 17 (34) 50 (54)
Ileum 9 (53) 8 (47) 17 (18)
Hereditary syndromes
Lynch syndrome 1 (25) 3 (75) 4 (4)
0.265FAP 1 (50) 1 (50) 2 (2)
No 56 (64) 31 (36) 87 (94)
Crohn’s disease
Yes 3 (75) 1 (25) 4 (4)
1.000 **No 55 (62) 34 (38) 89 (95)
Coeliac disease
Yes 4 (44) 5 (56) 9 (10)
0.289 **No 54 (64) 30 (36) 84 (90)
* Mantel–Haenszel test was used; ** Fisher’s exact test was used; TNM stage in eleven, grade in four and location in
nine tumours was unknown. ICS was undeterminable from one tumour. Abbreviations: ICS, immune cell score;
TNM, tumour-nodes-metastasis; MMR, mismatch repair; MSS, microsatellite stable; MSI, microsatellite instability;
FAP, Familial adenomatous polyposis.
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Table 2. Association of clinicopathological variables to Immunoprofile.
Immunoprofile
0
Immunoprofile
1
Immunoprofile
2
Immunoprofile
3 Total p-Value
n = 47 n = 18 n = 13 n = 14 n = 92
(% of Row) (% of Row) (% of Row) (% of Row) (% ofColumn)
Age
<60 years 18 (49) 8 (22) 5 (14) 6 (16) 37 (40)
0.967≥60 years 29 (53) 10 (18) 8 (15) 8 (15) 55 (60)
Sex
Female 23 (54) 9 (21) 5 (12) 6 (14) 43 (47)
0.894Male 24 (49) 9 (18) 8 (16) 8 (16) 49 (53)
TNM stage
I 1 (25) 1 (25) 0 (0) 2 (50) 4 (5)
0.003 *
II 8 (40) 3 (15) 4 (20) 5 (25) 20 (25)
III 8 (35) 5 (22) 6 (26) 4 (17) 23 (28)
IV 22 (65) 8 (24) 2 (6) 2 (6) 34 (42)
Tumour grade
1 8 (47) 4 (24) 4 (24) 1 (6) 17 (19)
0.544 *2 29 (53) 9 (16) 8 (15) 9 (16) 55 (63)
3 7 (44) 4 (25) 1 (6) 4 (25) 16 (18)
MMR status
MSS 45 (58) 18 (23) 8 (10) 7 (9) 78 (85)
<0.001MSI 2 (14) 0 (0) 5 (36) 7 (50) 14 (15)
Location
Duodenum 7 (41) 3 (18) 4 (24) 3 (18) 17 (21)
0.563Jejunum 27 (55) 9 (18) 6 (12) 7 (14) 49 (59)
Ileum 7 (41) 5 (35) 1 (6) 3 (18) 17 (21)
Lynch syndrome
no 47 (53) 18 (21) 11 (13) 12 (14) 88 (96)
0.018yes 0 (0) 0 (0) 2 (50) 2 (50) 4 (4)
Crohn’s disease
no 45 (51) 17 (19) 13 (15) 13 (15) 88 (96)
0.821yes 2 (50) 1 (25) 0 (0) 1 (25) 4 (4)
Coeliac disease
no 43 (52) 17 (21) 11 (13) 12 (15) 83 (90)
0.745yes 4 (44) 1 (11) 2 (22) 2 (22) 9 (10)
* Mantel–Haenszel test was used; TNM stage in eleven, grade in four and location in nine tumours was unknown.
Immunoprofile was undeterminable from two tumours.
The associations of TMB with clinicopathological variables are shown in Table 3. High TMB
was strongly associated with MSI tumours, high ICS, high PD-L1IC and PD-1 expression and high
Immunoprofile. Four (5%) of the MSS tumours had high TMB. High TMB was also associated with
coeliac disease with five (56%) tumours expressing high TMB (p = 0.012, Table 3).
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Table 3. Association of tumour mutational burden with clinicopathological variables.
TMB-Low TMB-High Total p-Value
(% of Row) (% of Row) (% of Column)
Age
<60 years 32 (82) 7 (18) 39 (41)
0.803≥60 years 44 (80) 11 (10) 55 (59)
Sex
Female 36 (82) 8 (18) 44 (47)
0.823Male 40 (80) 10 (20) 50 (53)
pTNM stage
I 3 (75) 1 (25) 4 (5)
0.674 *
II 16 (80) 4 (20) 20 (24)
III 18 (75) 6 (25) 24 (29)
IV 29 (83) 6 (17) 35 (42)
Tumour grade
1 15 (88) 2 (12) 17 (19)
0.166 *2 46 (81) 11 (19) 57 (63)
3 11 (69) 5 (31) 16 (18)
MMR
MSS 76 (95) 4 (5) 80 (85)
<0.001MSI 0 (0) 14 (100) 14 (15)
ICS
Low 52 (90) 6 (10) 58 (62)
0.005High 23 (66) 12 (34) 35 (38)
PD-L1IC
Low 61 (88) 8 (12) 69 (74)
0.001High 14 (58) 10 (42) 24 (26)
PD-L1TC
Low 70 (81) 16 (19) 86 (92)
0.617High 5 (71) 2 (29) 7 (8)
PD-1
Low 60 (91) 6 (9) 66 (71)
<0.001High 15 (56) 12 (44) 27 (29)
Immunoprofile
0 44 (94) 3 (6) 47 (51)
<0.001 *
1 15 (83) 3 (17) 18 (20)
2 8 (62) 5 (39) 13 (14)
3 7 (50) 7 (50) 14 (15)
Tumour location
Duodenum 15 (88) 2 (12) 17 (20)
0.738Ileum 40 (80) 10 (20) 50 (59)
Jejunum 15 (83) 3 (17) 18 (21)
Coeliac disease
No 72 (85) 13 (15) 85 (90)
0.012 **Yes 4 (44) 5 (56) 9 (10)
Crohn’s disease
No 72 (80) 18 (20) 90 (96)
1.000 **Yes 4 (100) 0 (0) 4 (4)
Abbreviations: TMB, tumour mutational burden; ICS, immune cell score; PD-L1, programmed death ligand-1; IC,
immune cell; TC, tumour cell; PD-1, programmed cell death protein-1.* Mantel–Haenszel test was used; ** 2-sided
Fisher’s Exact test was used. TNM stage in eleven, grade in four and location in nine tumours was unknown. ICS
and PD-1 were indeterminable from one tumour, as was PD-L1. The Immunoprofile was therefore missing for
two tumours.
Cancers 2020, 12, 2018 7 of 19
No significant associations were found between the KRAS, APC, or TP53 mutations and ICS,
PD-L1IC, PD-1, or Immunoprofile. Correlations between different mutation types in the coding regions
and mutational signatures and immune markers are shown in Table S1a for MSS tumours and in Table
S1b for MSI tumours. Only mutational signature 17 had a weak correlation with PD-L1IC (rs = 0.318, p
= 0.004) and Immunoprofile (rs = 0.269, p = 0.017) in MSS tumours.
2.2. Univariable Survival Analyses
Kaplan–Meier survival analyses with clinicopathological variables are shown in Supplementary
Materials Table S2. High ICS, high PD-L1IC, high PD-1 and high Immunoprofile (Figure 1) were
significantly prognostic for better patient outcome (5-year disease-specific survival (DSS) of 70% versus
30%, 81% versus 33%, 80% versus 31% and 93% versus 26% and 5-year overall survival (OS) of 68%
versus 25%, 77% versus 28%, 74% versus 27% and 93% versus 21%, respectively, p < 0.001 for all).
Median OS for low ICS, low PD-L1IC, low PD-1 and low Immunoprofile were 27, 31, 31 and 27 months,
respectively, and median DSS was 31 months for all. For high ICS, high PD-L1IC, high PD-1 and
high Immunoprofile median OS or DSS were not reached. Similarly, patients with high TMB had an
improved DSS (5-year survival of 39% versus 77%, p = 0.009) and OS (5-year survival of 33% versus
72%, p = 0.003). Median DSS for low TMB was 41 and median OS 33 months, for high TMB median
DSS or OS were not reached. A high TNM stage was prognostic for poor survival, with stage IV having
only a 7% 5-year DSS and OS (p < 0.001 for both, median DSS 15 and median OS 13 months). Tumour
MSI status was prognostic for better DSS (5-year survival of 39% versus 85%, p = 0.003) and OS (5-year
survival of 34% versus 79%, p = 0.001). Median DSS for MSS tumours was 41 and median OS 34
months, for MSI tumours median DSS or OS were not reached. Tumour location in the duodenum
or jejunum rather than in the ileum had a better DSS (5-year survival of 50% and 52% versus 34%,
p = 0.045) and OS (5-year survival of 47% and 51% versus 21%, p = 0.014). Median DSS for duodenal
tumours was not reached, for jejunal tumours 68 months and for ileal tumours 22 months. Median OS
for duodenal, jejunal and ileal tumours were 48, 55 and 21 months, respectively. Furthermore, patients
with coeliac disease had a favourable prognosis for DSS (5-year survival of 78% versus 42%, p = 0.045)
and OS (5-year survival of 78% versus 37%, p = 0.014). Median DSS or OS for coeliac disease were
not reached. For other than coeliac disease associated tumours, median DSS was 45 and median OS
36 months.
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Figure 1. Disease-specific and overall survivals according to Immunoprofile.
2.3. Multivariable Survival Analysis
According to the univariable analysis, TNM Stage, MMR status, ICS, PD-1, PD-L1IC and tumour
location were included in the multivariable analysis together with age and sex. Coeliac disease
was excluded because of the small sample size, especially after the exclusion of tumours with
inadequate data.
Table 4 shows the multivariable model with separate immune parameters, ICS, PD-1 and PD-L1IC.
Of the immune parameters, only PD-L1IC was found to be an independent prognostic marker with
DSS, with a hazard ratio (HR) of 4.73 (p = 0.020) and an OS HR of 3.88 (p = 0.018). Stage IV, with respect
to stage I as a reference, was highly prognostic for poor DSS and OS (HR 17.16, p = 0.001 and HR 6.64,
p < 0.001). Tumour location in the ileum was prognostic for worse patient outcome (HR 8.25 for DSS, p
< 0.001 and HR 5.76 for OS, p = 0.001). In addition, MSS tumours had a worse OS (12.18, p = 0.025).
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Table 4. Multivariable analysis with Immune cell score, PD-1 and PD-L1IC.
Univariable
Analysis
Disease-Specific Survival Overall Survival
(n = 68) (n = 68)
P HR (95% CI) p-Value HR (95% CI) p-Value
Age
<60 years DSS: 0.614
OS: 0.640
1
0.146
1
0.052≥60 years 1.89 (0.80–4.47) 2.22 (0.99–4.96)
Sex
Female DSS: 0.829
OS: 0.536
1
0.251
1
0.446Male 0.65 (0.31–1.35) 0.76 (0.38–1.54)
TNM stage
I
DSS: <0.001
OS: <0.001
1
0.001
1
<0.001II
2.03
(0.18–22.44) 0.62 (0.11–3.42)
III 3.15(0.30–32.67) 0.85 (0.16–4.52)
IV 17.16(1.44–204.47)
6.64
(1.08–41.07)
MMR status
MSS DSS: 0.010
OS: 0.004
5.83
(0.66–51.41) 0.112
12.18
(1.37–108.21) 0.025
MSI 1 1
Immune cell score
low DSS: 0.001
OS: <0.001
1.96 (0.79–4.85)
0.145
2.33 (0.98–5.57)
0.056high 1 1
PD-1
low DSS: <0.001
OS: <0.001
1.13 (0.27–4.78)
0.868
0.51 (0.14–1.84)
0.307high 1 1
PD-L1IC
low DSS: <0.001
OS: <0.001
4.73
(1.27–17.57) 0.020
3.88
(1.26–11.93) 0.018
high 1 1
Tumour location
Duodenum
DSS: 0.043
OS: 0.015
1
<0.001
1
<0.001Jejunum 0.88 (0.25–3.08) 1.00 (0.31–3.21)
Ileum 7.83(1.55–39.62)
7.26
(1.57–33.54)
Abbreviations: HR, hazard ratio; CI, confidence interval; DSS, disease-specific survival; OS, overall survival; MMR,
mismatch repair; MSS, microsatellite stable; MSI, microsatellite instable; PD-1, programmed cell death protein
1; PD-L1, programmed death ligand 1; IC, immune cell. Analyses were performed with the following reference
categories: <60 years, female gender, TNM Stage I, MSI status, high Immune cell score, high PD-1, high PD-L1IC
and duodenal tumour location. For analyses there were 68 patients available. Eleven patients were excluded
because of unknown TNM stage, one patient had insufficient samples for Immune cell score and PD-1, one patient
had insufficient samples for PD-L1IC, nine patients had unknown tumour location, three patients had insufficient
survival data, and two patients were excluded because of post-operative death.
Table 5 shows the multivariable model with Immunoprofile adjusted for age, gender, TNM stage,
MMR status and tumour location. Immunoprofile was dichotomized into low (classes 0 and 1) and high
(classes 2 and 3) groups, because after the exclusion of the tumours with inadequate data, the original
groups sizes were small. Furthermore, according to the Kaplan–Meier analysis, the DSS and OS among
low and high Immunoprofile classes were at a similar level (Supplementary Table S2). The prognostic
effect of Immunoprofile was enhanced compared to the effect of separate immune parameters. For DSS,
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low Immunoprofile had an HR of 6.34 (p = 0.008) and for OS HR of 3.57 (p = 0.022). The TNM stage
remained as an independent prognostic factor (stage IV HR 32.91 for DSS and 13.24 for OS, p < 0001 for
both) as well as tumour location in the ileum (HR 3.37 for DSS, p = 0.001 and HR 2.83 for OS, p = 0.002).
Age > 60 was prognostic for worse DSS (HR 2.44, p = 0.038) and OS (HR 2.61, p = 0.018).
Table 5. Multivariable analysis with Immunoprofile.
Univariable
Analysis
Disease-Specific Survival Overall Survival
(n = 68) (n = 68)
P HR (95% CI) p-Value HR (95% CI) p-Value
Age
<60 years DSS: 0.614
OS: 0.640
1
0.038
1
0.018≥60 years 2.44 (1.05–5.67) 2.61 (1.18–5.79)
Sex
Female DSS: 0.829
OS: 0.536
1
0.053
1
0.091Male 0.49 (0.24–1.01) 0.55 (0.28–1.10)
TNM stage
I
DSS: <0.001
OS: <0.001
1
<0.001
1
<0.001II
2.79
(0.27–28.68) 1.03 (0.20–5.36)
III 6.26(0.66–59.29) 2.06 (0.45–9.42)
IV 32.91(2.88–375.66)
13.24
(2.23–78.55)
MMR status
MSS DSS: 0.010
OS: 0.004
5.23
(0.57–47.57) 0.142
8.90
(1.00–79.39) 0.050
MSI 1 1
Immunoprofile
Low DSS: <0.001
OS: <0.001
6.34
(1.61–24.97) 0.008
3.57
(1.20–10.62) 0.022
High 1 1
Tumour location
Duodenum
DSS: 0.043
OS: 0.015
1
0.001
1
0.002Jejunum 0.58 (0.18–1.90) 0.57 (0.19–1.74)
Ileum 3.37(0.79–14.32)
2.83
(0.70–11.41)
Abbreviations: HR, hazard ratio; CI, confidence interval; DSS, disease-specific survival; OS, overall survival;
MMR, mismatch repair; MSS, microsatellite stable; MSI, microsatellite instable. Analyses were performed with
the following reference categories: <60 years, female gender, TNM Stage I, MSI status, high Immunoprofile and
duodenal tumour location. For analyses there were 68 patients available. Eleven patients were excluded because of
unknown TNM stage, two patients were excluded because of insufficient samples for Immunoprofile, nine patients
had unknown tumour location, three patients had insufficient survival data and two patients were excluded because
of postoperative death.
Of the 14 MSI tumours, four were excluded because of insufficient data. Among those were
two of the three MSI patients who succumbed during follow-up including one MSI tumour with an
SBA related death and low Immunoprofile. Mismatch repair status was not prognostic in a model
with Immunoprofile, and all but one MSI tumour left in the model had a high Immunoprofile. In a
multivariable model with separate immune parameters but without MMR status, PD-L1IC remained
the only independent prognostic factor (HR 5.87, p = 0.009 for DSS and HR 4.94, p = 0.007 for OS,
Supplementary Materials Table S3). In a model with Immunoprofile and with the MMR status removed,
the effect of Immunoprofile was even more pronounced, with low Immunoprofile having an HR of
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11.96 for DSS and an HR of 7.54 for OS, p < 0.001 for both (Supplementary Materials Table S4). Impact
of coeliac and Crohn’s disease were evaluated in an additional multivariable model but both were left
insignificant (Supplementary Materials Table S5).
3. Discussion
Our results indicate that analysing tumour immune contexture may be helpful in predicting tumour
behaviour in SBA. Immune cell infiltration and high PD-1 and PD-L1 expression in tumour-infiltrating
lymphocytes were common in MSI tumours and were associated with a lower TNM stage. All the
immune parameters were highly prognostic in the univariable survival analysis, yet only PD-L1IC
remained an independently significant single marker in the multivariable model for DSS and OS in
the presence of MMR status. High ICS, PD-1 positivity and PD-L1 expression in tumour-infiltrating
lymphocytes all had strong relationships with each other, causing a possible confounding effect when
evaluated together. However, Immunoprofile, determined as a combination of ICS, PD-1 and PD-L1IC,
enhanced the effect of single variables and proved to be a strong independent prognostic factor for
DSS and OS as we have previously reported in CRC [25].
An earlier study of the SBA immune environment reported a high expression of PD-1 in peritumoral
and intratumoral lymphocytes (83%) and PD-L1 in both tumour cells (17%) and tumour-infiltrating
lymphocytes (43%) [28]. We used a cut-off value of >5% for PD-L1 positivity with moderate-to-strong
staining intensity, which was more informative in the survival analysis and provided comparative
results with earlier reports in our previous study performed on CRC [25]. However, with the same
cut-off value of 1% used by Thota et al. [28] for PD-L1 positivity, our sensitivity analyses showed
positive PD-L1TC in 15% and positive PD-L1IC in 69% of the tumours with at least moderate staining
intensity. When including tumours with weak staining intensity, a ≥1% expression of PD-L1TC was
seen in 21% and PD-L1IC in 85% of the tumours. Our study population had a significantly higher
share of stage IV tumours (37% versus 20%) than the SBA cohort presented by Thota et al. [28]. Of the
stage IV tumours, 42% expressed ≥1% positive PD-L1IC, and 20% expressed ≥1% positive PD-L1TC
with moderate-to-strong staining intensity. As the PD-1/PD-L1 pathway provides a possible immune
escape route for tumours, it is expected that PD-L1 expression in advanced disease is increased.
Although PD-1/PD-L1 expression should suppress the immune reaction against tumours, the
reports of the prognostic value of PD-L1 expression vary among different cancer types. The expression
of PD-L1 has been shown to correlate with a poor prognosis in oesophageal cancer, pancreatic
carcinoma, hepatocellular carcinoma, renal cell carcinoma and ovarian cancer [29–34]. However, PD-L1
correlated with better patient outcome in breast cancer and Merkel cell carcinoma [35,36]. For lung
cancer, melanoma, gastric cancer and CRC both positive and negative prediction values have been
reported [37–45].
One possible reason for this discrepancy between results may be explained by the large variation
of definitions of PD-L1 positivity, with the cut-off for positive staining varying from 1% to 50%.
In some studies, staining was considered positive only with moderate-to-strong staining intensity,
while others considered also weak staining intensity as positive. In addition, some have evaluated
only the overall positivity of the tumour sample, while others have identified positive tumour
cells and positive immune cells separately [46,47]. It has also been reported that PD-L1 not only
inhibits T-cell proliferation and cytokine production, but also enhances T-cell activation, and the
explanation for this is still unknown [48]. Considering all the contradictory information, it is clear
that the function of the PD-1/PD-L1 pathway is not yet fully understood. In our study, the obvious
explanation for the favourable effect of positive PD-L1IC and PD-1 would be the close association of
PD-1/PD-L1 expression with a large amount of tumour-infiltrating lymphocytes, so that PD-1/PD-L1
expression rather reflects enhanced host immune reaction against tumour cells, which is balanced by
tumour-derived immune suppression.
Microsatellite unstable tumours are characterized by an extensive mutational load, leading to
truncating mutations that are identified by the immune surveillance because of misfolded proteins
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serving as neoantigens, causing enhanced antitumoral immune reaction and, therefore, improved
survival. This was noted also in our results, as MSI status was associated with high ICS, a high number
of PD-1 positive immune cells and PD-L1IC expression. The incidence of MSI tumours was 15%,
which is in accordance with earlier reports [20]. Response to immune checkpoint inhibitors correlates
with TMB, MMR status and PD-L1 expression. There is evidence that even very low (1%) PD-L1IC
positivity may be sufficient to predict the efficiency of PD-L1 blockade, and that the adverse effects of
the treatments seem to be higher with PD-L1 negative patients [49]. In a large study by Salem et al. [50],
4125 tumours from 14 different cancer sites, including 147 SBAs, were quantified for TMB, MMR status
and PD-L1 expression. They found that SBA had one of the highest TMB rates (14% with a cut-off of
17 mutations/Mb), and TMB was strongly associated with MSI status [50]. In our study, we selected
a cut-off of 10 mutations/Mb, which in a trial of nivolumab plus ipilimumab in non-small-cell lung
cancer-selected patients was most likely to have a response irrespective of tumour PD-L1 expression
level [51]. As expected, high TMB was associated with MSI and a better Immunoprofile with high ICS,
PD-L1IC and PD-1. High TMB was discovered in 18 (19%) SBAs including all the 14 MSI tumours.
Every MSI tumour had at least 22.84 mutations/Mb, qualifying as having a high TMB status also with
several large mutational landscape studies [50,52,53]. As the MSI status is relatively frequent, the TMB
rates are high and PD-L1IC positivity is common, selected SBAs could potentially be good responders
for checkpoint inhibitor therapy.
Despite many similarities, SBAs have a distinct mutational landscape compared to CRC or gastric
cancer [27]. We found that the only notable correlation between different mutation patterns and
immune parameters was the correlation of mutational signature 17 with PD-L1IC, and, therefore, with
Immunoprofile in MSS tumours. Signature 17 has been found also in both CRC and gastric cancers,
but the meaning and the process causing it is still unclear [27,54]. High ICS was associated with high
TMB, but we found no correlations between high immune cell infiltration and specific mutation types.
Some tumours with high TMB had a low ICS and Immunoprofile. However, all three Immunoprofile 0
tumours with a high TMB were at an advanced TNM stage (III or IV), indicating successful cancer
immune evasion.
It is known that coeliac disease increases the risk of SBA, especially in refractory coeliac disease
where mucosal damage remains even with a strict gluten-free diet [55]. However, the prognosis of
coeliac disease associated with SBA seems to be significantly improved compared to SBA without
coeliac disease [56,57]. This was explained by the high frequency of MSI tumours (73%) and overall
lower TNM stage upon discovery [56]. In our study, coeliac-associated tumours showed better survival
in the univariable analysis, but the number of tumours was too small to be included in further analysis.
The proportion of MSI tumours was 44% (4/9), and only one of the tumours was at stage IV. Four of the
patients had an Immunoprofile of 0 (three stage III and one stage IV tumour), including the only two
coeliac disease patients with SBA-related death during follow-up. None of the tumours expressed
high PD-L1TC, which presented a trend for worse DSS in the univariable analysis. It is also possible
that improved survival is related to the enhanced clinical follow-up of coeliac disease patients, i.e.,
SBA is diagnosed at an earlier stage.
Tumour location in the ileum was prognostic for worse survival for DSS and OS, resulting in the
high portion of stage IV tumours in the ileum. Most of the coeliac-associated tumours were located in
the jejunum (67%), which is in accordance with previous studies [56,57]. The overall distribution of
SBAs in our study differs from large epidemiological studies, where the duodenum is the most common
location [3,4]. The higher incidence of duodenal tumours may be related to the abundant exposure
to bile [58]. Here, 53% of the tumours were located in the jejunum and only 18% in the duodenum,
arguably reflecting our small cohort size. However, exclusion of the tumours of the papillary region
may have contributed to the difference.
A weakness of this study is the deficiency of the clinical data, and therefore less than a quarter of
the study population were excluded from the multivariable analysis. In addition, because the tumour
type is rare, the study population was small to begin with, and the study is retrospective, the results can
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be considered only as suggestive. However, we provide new information on SBA, as we have analysed
survival data of SBAs with a previously characterized mutational profile in the context of the immune
landscape with ICS, PD-1 and PD-L1IC positivity determined from whole-section FFPE samples. Until
now, Immunoprofile [25] has lacked validation in an independent dataset that we now present herein,
suggesting that Immunoprofile is a scalable predictor of cancer outcome across tumour types.
4. Material and Methods
4.1. Patients
The tumours used in the present study were derived from a nation-wide series of 106 SBAs treated
in Finnish hospitals between 2003 and 2011, described previously [27]. In 94 cases, representative
tumour samples were still available for immunohistochemical analyses. Tumours of the papillary
region were excluded since they may have originated in the pancreas or the biliary tract. The median
age of the patients during surgery was 62 (interquartile range 54–73) and there was a slight female
predominance (53%). The median follow-up time after surgery was 44 months (interquartile range
16–84 months). Nine tumours (10%) were associated with coeliac disease and four (4%) with Crohn’s
disease. Four patients (4%) had LS and two (2%) had FAP. Fourteen tumours (15%) were MSI. The
tumour location was the duodenum in 18%, the jejunum in 53%, the ileum in 19% and undetermined
in 10% of cases. Tumours with coeliac disease were mainly located in the jejunum (67%) and tumours
with Crohn’s disease were found equally in the jejunum and ileum. Stage distribution was I 4%, II 21%,
III 26%, IV 37% and unknown in 12%. Three patients died post-operatively, and three patients had
insufficient survival data and were excluded from the survival analysis. Ten mutations per megabase
(Mb) was selected as a cut-off to determine high TMB.
4.2. Immunohistochemical Analyses
Formalin-fixed paraffin-embedded (FFPE) tissue sections of 3 µm thickness were used for the
immunohistochemical analyses. Staining for PD-1 and PD-L1 was conducted with anti-PD-1 (SP269,
1:50; Spring Bioscience) and anti-PD-L1 (E1L3N, 1:100; Cell Signaling Technology) antibodies, using a
BOND-III stainer (Leica Biosystems). Staining for CD3 and CD8 was conducted with anti-CD3 (LN
10, 1:200; Novocastra) and anti-CD8 (SP16, 1:400; Thermo Scientific) antibodies using a Lab Vision
Autostainer 480 (ImmunoVision Technologies Inc.). Signal visualization was done by diaminobenzidine,
and sections were counterstained with haematoxylin. The slides were scanned with a NanoZoomer-XR
(Hamamatsu Photonics) at 20× magnification (Figure 2).
4.3. Scoring
Scoring was done as described earlier [25]. Briefly, representative areas from the tumour centre
and the invasion margin were selected, and positively stained CD8, CD3 and PD-1 lymphocytes were
calculated by using QuPath [59]. The invasive margin was selected manually using an annotation
brush with a diameter of 720 µm. The analyses were done by two examiners and interrater reliability
(IRR) was evaluated by determining the intraclass correlation coefficient. Inter-rater reliabilities for the
analyses of CD3, CD8 and PD-1 tumour centre were 0.96 (CI95% 0.93–0.97), 0.98 (CI95% 0.96–0.99)
and 0.73 (CI95% 0.57–0.83), respectively. Inter-rater reliabilities for analyses of the CD3, CD8 and
PD-1 invasive margin were 0.89 (CI95% 0.83–0.92), 0.90 (CI95% 0.84–0.94) and 0.75 (CI95% 0.58–0.84),
respectively. The mean analysed areas for the tumour centre from CD3-, CD8-, and PD-1-stained
sections were 24.9 mm2, 22.3 mm2 and 18.5 mm2, and for the invasion margin 12.2 mm2, 11.8 mm2
and 10.5 mm2, respectively. Cut-off values for ICS were selected from receiver operating characteristic
curves (715 for CD3+, 255 for CD8+, and 48 for PD-1+ in the tumour centre; 1327 for CD3+, 598 for
CD8+, and 27 for PD-1+ in the invasive margin). Cut-off values were the same for 5 and 10 year
disease-specific survival related ROC curves. Patients were divided into low ICS (scores 0–2) and high
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ICS (scores 3–4) groups for further analysis. Expression of PD-1 was considered positive if the cell
count was high on both the tumour centre and invasive margin.
Cancers 2020, 11, x FOR PEER REVIEW  12 of 17 
Cancers 2020, 11, x; doi: FOR PEER REVIEW  www.mdpi.com/journal/cancers 
slight  female  predominance  (53%).  The  median  follow‐up  time  after  surgery  was  44  months 
(interquartile range 16–84 months). Nine  tumours  (10%) were associated with coeliac disease and 
four (4%) with Crohn’s disease. Four patients (4%) had LS and two (2%) had FAP. Fourteen tumours 
(15%) were MSI. The tumour location was the duodenum in 18%, the jejunum in 53%, the ileum in 
19% and undetermined  in 10% of cases. Tumours with coeliac disease were mainly  located  in the 
jejunum (67%) and tumours with Crohn’s disease were found equally in the jejunum and ileum. Stage 
distribution was  I  4%,  II  21%,  III  26%,  IV  37%  and  unknown  in  12%. Three patients died  post‐
operatively, and three patients had insufficient survival data and were excluded from the survival 
analysis. Ten mutations per megabase (Mb) was selected as a cut‐off to determine high TMB. 
4.2. Immunohistochemical Analyses 
Formalin‐fixed paraffin‐embedded (FFPE) tissue sections of 3 μm thickness were used for the 
immunohistochemical analyses. Staining for PD‐1 and PD‐L1 was conducted with anti‐PD‐1 (SP269, 
1:50; Spring Bioscience) and anti‐PD‐L1 (E1L3N, 1:100; Cell Signaling Technology) antibodies, using 
 BOND‐III stainer (Leica Biosystems). Staining for CD3 and CD8 was conducted with anti‐CD3 (LN 
10, 1:200; Novocastra) and anti‐CD8 (SP16, 1:400; Thermo Scientific) antibodies using a Lab Vision 
Autostainer  480  (ImmunoVision  Technologies  Inc.).  Signal  visualization  was  done  by 
diaminobenzidine, and sections were counterstained with haematoxylin. The slides were scanned 
with a NanoZoomer‐XR (Hamamatsu Photonics) at 20× magnification (Figure 2). 
 
Figure  2. Examples  of CD3  (A), CD8  (B)  and PD‐1  (C)  stainings.  (D) PD‐L1 positive  staining  in 
immune cells and (E) PD‐L1 positive staining in tumour cells. Images were captured with 8× zoom 
from 20× magnified scanned slides. 
4.3. Scoring 
Scoring was done as described earlier [25]. Briefly, representative areas from the tumour centre 
and the invasion margin were selected, and positively stained CD8, CD3 and PD‐1 lymphocytes were 
calculated by using QuPath [59]. The  invasive margin was selected manually using an annotation 
brush with a diameter of 720 μm. The analyses were done by two examiners and interrater reliability 
(IRR) was evaluated by determining the intraclass correlation coefficient. Inter‐rater reliabilities for 
the analyses of CD3, CD8 and PD‐1 tumour centre were 0.96 (CI95% 0.93–0.97), 0.98 (CI95% 0.96–
0.99) and 0.73 (CI95% 0.57–0.83), respectively. Inter‐rater reliabilities for analyses of the CD3, CD8 
and PD‐1 invasive margin were 0.89 (CI95% 0.83–0.92), 0.90 (CI95% 0.84–0.94) and 0.75 (CI95% 0.58–
0.84),  respectively. The mean  analysed  areas  for  the  tumour  centre  from CD3‐, CD8‐,  and PD‐1‐
stained sections were 24.9 mm², 22.3 mm2 and 18.5 mm², and for the invasion margin 12.2 mm², 11.8 
mm2  and  10.5 mm²,  respectively.  Cut‐off  values  for  ICS were  selected  from  receiver  operating 
Figure 2. Examples of CD3 (A), CD8 (B) and PD-1 (C) stainings. (D) PD-L1 positive staining in immune
cells and (E) PD-L1 positive staining in tumour cells. Images were captured with 8× zoom from 20×
magnified sc n ed slides.
Expression of PD-L1 was evaluated on tumour cells (TCs) and tumour-infiltrating immune cells
(ICs) throughout the tumour centre and the invasive margin. Both the percentage of stained immune
and tumour cells and the staining intensity were visually estimated. Tumour samples were defined as
PD-L1 positive when >5% of the tumour cells and/or tumour-infiltrating immune cells were positive
for PD-L1 with moderate or strong intensity [25].
As established previously, ICS, PD-1 cell count and PD-L1 expression in tumour infiltrating
lymphocytes were combined into a single immune parameter called Immunoprofile [25]. High ICS,
high PD-1 and positive PD-L1IC each accounted for 1 point. As an example, when ICS and PD-1 were
high and PD-L1IC was positive, the Immunoprofile was 3, and when ICS and PD-1 were low and
PD-L1IC negative, the Immunoprofile was 0 [25]. Immunoprofile was further categorised as low (0–1)
or high (2–3). Immune cell score and PD-1 were indeterminable from one tumour, as was PD-L1. The
Immunoprofile was therefore missing for two tumours.
4.4. Statistical Analysis
Categorical data were compared using Pearson’s chi-square or Mantel–Haenszel tests. Fisher’s
exact test was used for variables with a low observation rate. The Spearman correlation coefficient (rs)
was used to determine correlations between mutational data and immune variables. The Kaplan–Meier
method was used to calculate disease-specific survival (DSS) and overall survival (OS), and the log-rank
test was used to compare differences. A p-value < 0.05 was considered as a threshold of statistical
significance. Survival times for DSS and OS were calculated from the date of surgery to the time of
death or the end of follow-up. Death within 30 days following surgery was considered post-operative.
Univariable and multivariable Cox proportional hazards regression models were used to analyse
prognostic factors for DSS and OS. Only variables with a p-value < 0.20 in the univariable analysis
were included in the multivariable analysis with age and gender. Statistical analyses were performed
using IBM SPSS Statistics (version 25.0; SPSS Inc., Chicago, IL, USA).
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4.5. Ethical Aspects
The study was reviewed and approved by the Ethics Committee of the Hospital District of
Helsinki and Uusimaa, Finland (408/13/03/03/2009). Authorization for the use of the patient registry
and genetic studies was obtained from the National Supervisory Authority for Welfare and Health
(Valvira). Informed patient consent was waived by the Ethics Committee.
5. Conclusions
In conclusion, we found that a high portion of SBAs express ≥1% of PD-L1 in immune cells within
the tumour environment, and a high TMB is relatively common, although mainly seen in MSI tumours.
Therefore, SBA tumours might be good responders to immune checkpoint therapy. High ICS, PD-L1IC,
PD-1 and Immunoprofile were associated with a high TMB. The only correlation between mutation
types and signatures and immune parameters was the weak correlation of mutational signature 17
and PD-L1IC in MSS tumours. However, the true significance of this finding is unclear and requires
further research.
Immune cell score, PD-1 and PD-L1IC were prognostic for DSS and OS in the univariable analysis,
but only PD-L1IC remained so in the multivariable analysis. Still, the high interaction among immune
markers may cause a confounding effect. By combining the immune markers into a single variable
called Immunoprofile, the prognostic effect was enhanced. Immunoprofile, adjusted for TNM stage,
MMR status, tumour location, sex and age, was an independent prognostic marker for DSS and OS
in SBA.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/8/2018/s1,
Table S1a. Correlations between immune parameters and different mutation types and detected mutational
signatures in MSS tumours. Table S1b. Correlations between immune parameters and different mutation types in
MSI tumours. Table S2. Survival according to clinicopathological variables. Table S3. Multivariable analysis with
Immune cell score, PD-1 and PD-L1IC and without separate MMR status. Table S4. Multivariable analysis with
Immunoprofile, without MMR status. Table S5. Multivariable analysis with coeliac and Crohn’s disease.
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